|Day Low/High||72.74 / 73.81|
|52 Wk Low/High||52.83 / 81.29|
Why are big institutions running and can you outrace them?
Selecting the creme de la creme of last year's top dividend dogs generated an average total return of 8.8%.
The real takeaway for AMZN for me, and the main reason that I am even in the name on a semi-permanent basis, is AWS.
How do the charts and indicators look ahead of their quarterly release?
One of pharma's biggest CEO's talks M&A action on the exchange.
And it is happening not a moment too soon.
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
People will still take their medicine regardless of the state of the economy.
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
Look for the big-cap stocks that only come in on tough days -- and take advantage of their weakness at the open.
Use it to your advantage or don't use it at all.
Anticipating a weaker dollar thanks to the shift in the Fed, which stocks are most likely to benefit?
Pfizer pushes higher on price increases.
Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Eli Lilly's confirmation of acquisition action could make pharmaceuticals an attractive investment space.
Once the safest stocks in the book, the big-cap drug companies are now toxic.
It becomes difficult for me to tell you where to run in these markets...
There is clear divergence between the best and the worst performers in each sector this earnings season.
Straying from these names could land you in quicksand as the 4th quarter begins.
The industry has taken to smaller, voluntary measures to avoid serious federal action on pricing.
The answer is plenty, but you can't trade that.
Merck is vey overbought on a number of time frames.
Merck shares retreat as regulatory approval ramps up speculation.
There's too much evidence of economic strength, so don't interpret these moves as a sign of a real slowdown.